Frailty among patients with SLE was linked to subclinical cardiovascular disease based on SLICC-FI scores — a tool that may aid in cardiovascular risk assessment.

聚焦2024ACR SLE领域前沿进展。

Learn how hydroxychloroquine prevents lupus relapses after glucocorticoid withdrawal in inactive SLE patients. Explore ...

Objective Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by a loss of immune tolerance, affecting ...

The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...

Belimumab combined with SOC was successful for inducing remission among patients with SLE, including those with LN.

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

Younger men and Hispanic/Latino and non-Hispanic Black patients with SLE have greater rates of cardiovascular disease events compared with the general population.

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

The ACR has released a summary of a new 2024 guideline for the screening, treatment, and management of Lupus Nephritis.

UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second ...